Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: adalimumab
DATE: 08/07/2019
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
